Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,

Published byPhebe Lamb Modified over 9 years ago

Similar presentations

Presentation on theme: "Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,"— Presentation transcript:

1 Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze, Lin Zhang, Shiny Nair, Tamara Monesmith, Ranjini Sundaram, Fred Miesowicz, Kavita M. Dhodapkar, and Madhav V. Dhodapkar Blood Volume 121(3):423-430 January 17, 2013 ©2013 by American Society of Hematology

2 Study schema. Joshua Richter et al. Blood 2013;121:423-430 ©2013 by American Society of Hematology

3 Changes in NKT cells. Joshua Richter et al. Blood 2013;121:423-430 ©2013 by American Society of Hematology

4 Changes in NK cells. Joshua Richter et al. Blood 2013;121:423-430 ©2013 by American Society of Hematology

5 Changes in other innate cells and cytokines. Joshua Richter et al. Blood 2013;121:423-430 ©2013 by American Society of Hematology

6 Clinical effects of therapy. Joshua Richter et al. Blood 2013;121:423-430 ©2013 by American Society of Hematology

7 Changes in T-cell immunity. Joshua Richter et al. Blood 2013;121:423-430 ©2013 by American Society of Hematology

Download ppt "Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,"

Similar presentations

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis by.

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis by.
Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):3102-3111.

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):
Blockade of osteopontin reduces alloreactive CD8 + T cell– mediated graft-versus-host disease by Fang Zhao, Yi Zhang, Hao Wang, Min Jin, Shan He, Yufang.

Blockade of osteopontin reduces alloreactive CD8 + T cell– mediated graft-versus-host disease by Fang Zhao, Yi Zhang, Hao Wang, Min Jin, Shan He, Yufang.
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,
SAP mediates specific cytotoxic T-cell functions in X- linked lymphoproliferative disease by Reza Sharifi, Joanna C. Sinclair, Kimberly C. Gilmour, Peter.

SAP mediates specific cytotoxic T-cell functions in X- linked lymphoproliferative disease by Reza Sharifi, Joanna C. Sinclair, Kimberly C. Gilmour, Peter.
Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,

Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,
How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.

How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.
Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A 2A receptor agonist regadenoson by Joshua J. Field, Gene.

Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A 2A receptor agonist regadenoson by Joshua J. Field, Gene.
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation by Xiaoou Zhou, Gianpietro.

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation by Xiaoou Zhou, Gianpietro.
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Regulation of Toll-like receptor–mediated inflammatory response by complement in vivo by Xinhua Zhang, Yuko Kimura, Chongyun Fang, Lin Zhou, Georgia Sfyroera,

Regulation of Toll-like receptor–mediated inflammatory response by complement in vivo by Xinhua Zhang, Yuko Kimura, Chongyun Fang, Lin Zhou, Georgia Sfyroera,
Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell–, and not B cell–, dependent antilymphoma immunity by Hong Qin, Soung-chul.

Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell–, and not B cell–, dependent antilymphoma immunity by Hong Qin, Soung-chul.
Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
The beauty of TLR agonists for CTCL

The beauty of TLR agonists for CTCL
Do HSCs divide asymmetrically?

Do HSCs divide asymmetrically?
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and
Dasatinib suppresses in vitro natural killer cell cytotoxicity

Dasatinib suppresses in vitro natural killer cell cytotoxicity
VEGF therapy: risky business for established plaques?

VEGF therapy: risky business for established plaques?

Similar presentations

Ads by Google